Two-year data confirm efficacy of novel MS drug

A new type of immunomodulator could be one of the first oral treatments for multiple sclerosis, if an approval application expected later this year is successful.

by
A once-daily pill could be a welcome alternative to parenteral treatments for patients with multiple sclerosis.
A once-daily pill could be a welcome alternative to parenteral treatments for patients with multiple sclerosis.

To continue enjoying this article, please sign in. You can register for free for limited further access, or subscribe now for full access to all our content.

Sign In

Trouble signing in?

Reset password: Click here

Need help? Email us

Register

FREE

  • Limited free articles a month 
  • Free email bulletins

Register Now

Subscribe now

Benefits include:

  • Full site access
  • Subscriber exclusive content
  • Exclusive bulletins

Choose a package